Drug Trial Radar · NCT05727891
Evaluation of Tonabersat for DME
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
129
Actual
Start
May 2, 2023
Primary completion
Jan 15, 2026
Study completion Jan 15, 2026
Sponsor
- Lead sponsor
- Jaeb Center for Health ResearchAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Institutes of Health (NIH); National Eye Institute (NEI); Juvenile Diabetes Research Foundation
- First posted
- Feb 14, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This randomized clinical trial will evaluate the effect of tonabersat compared with placebo on central subfield thickness (CST) in eyes with center-involved diabetic macular edema (CI-DME) and good visual acuity.
Conditions
- Diabetic Macular Edema
Interventions
TonabersatDrug
Two pills of Study Drug (80 mg tonabersat) is taken orally once daily. It is recommended the Study Drug be taken at bedtime. The first dose (two pills) will be taken at bedtime on the day the participant is randomized.
PlaceboOther
Two pills of Study Drug (placebo) is taken orally once daily. It is recommended the Study Drug be taken at bedtime. The first dose (two pills) will be taken at bedtime on the day the participant is randomized.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Optical Coherence Tomography Central Subfield Thickness Change From BaselineTime frame: 6 months
Locations
28 sites in 1 country. Site status is shown where the registry gives one.
Retina Associates of Southern California
Huntington Beach, California
Loma Linda University
Loma Linda, California
East Bay Retina Consultants, Inc.
Oakland, California
Southern California Desert Retina Consultants, Inc.
Palm Desert, California
Macula Retina Vitreous Institute
Torrance, California
National Ophthalmic Research Institute
Fort Myers, Florida
University of Florida- Jacksonville
Jacksonville, Florida
Central Florida Retina Institute
Lakeland, Florida
Florida Retina Consultants
Lakeland, Florida
Southeast Eye Institute, P.A. dba Eye Associates of Pinellas
Pinellas Park, Florida
Southeast Retina Center
Augusta, Georgia
Thomas Eye Group
Sandy Springs, Georgia
Illinois Retina Associates
Oak Park, Illinois
Midwest Eye Institute
Indianapolis, Indiana
Joseph E. Humble and Raymond Haik PTRS DBA Eye Assoc of Northeast Louisiana
West Monroe, Louisiana
Elman Retina Group
Baltimore, Maryland
Boston Medical Center Corporation
Boston, Massachusetts
Joslin Diabetes Center
Boston, Massachusetts
Mayo Clinic
Rochester, Minnesota
Retina Research Institute, LLC
St Louis, Missouri
Retina-Vitreous Surgeons of Central NY, PC
Liverpool, New York
Verum Research LLC
Eugene, Oregon
The Trustees of the University of Pennsylvania
Philadelphia, Pennsylvania
Pittsburg Clinical Trial Consortium
Sewickley, Pennsylvania
Hilton Head Retina Institute
Hilton Head Island, South Carolina
Retina Consultants of Texas, PA
Bellaire, Texas
Texas Retina Associates
Lubbock, Texas
Retinal Consultants of Texas
San Antonio, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.